Jason Farrar
Concepts (505)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 15 | 2024 | 208 | 2.880 |
Why?
| | Anemia, Diamond-Blackfan | 13 | 2024 | 13 | 2.530 |
Why?
| | Mutation | 19 | 2023 | 1338 | 1.760 |
Why?
| | Ribosomal Proteins | 9 | 2021 | 24 | 1.380 |
Why?
| | Venous Thromboembolism | 2 | 2021 | 78 | 1.250 |
Why?
| | Critical Illness | 7 | 2025 | 316 | 1.080 |
Why?
| | Public Health | 5 | 2025 | 231 | 1.040 |
Why?
| | Wounds and Injuries | 4 | 2025 | 301 | 1.010 |
Why?
| | Humans | 102 | 2025 | 53246 | 0.870 |
Why?
| | Midazolam | 1 | 2024 | 37 | 0.850 |
Why?
| | Pneumonia, Ventilator-Associated | 2 | 2025 | 18 | 0.840 |
Why?
| | Biomedical Research | 3 | 2025 | 267 | 0.840 |
Why?
| | Hypnotics and Sedatives | 1 | 2024 | 74 | 0.810 |
Why?
| | Anti-Infective Agents | 2 | 2022 | 107 | 0.800 |
Why?
| | Neurosurgical Procedures | 1 | 2024 | 137 | 0.770 |
Why?
| | Gene Expression Profiling | 7 | 2023 | 1112 | 0.750 |
Why?
| | Body Weight | 2 | 2021 | 524 | 0.720 |
Why?
| | Rhabdomyosarcoma, Alveolar | 1 | 2021 | 8 | 0.700 |
Why?
| | Li-Fraumeni Syndrome | 1 | 2021 | 11 | 0.700 |
Why?
| | Enoxaparin | 1 | 2021 | 32 | 0.660 |
Why?
| | Stenotrophomonas maltophilia | 1 | 2020 | 7 | 0.630 |
Why?
| | Vietnam | 21 | 2020 | 45 | 0.620 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2020 | 45 | 0.610 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2021 | 228 | 0.610 |
Why?
| | Anti-Bacterial Agents | 5 | 2025 | 832 | 0.590 |
Why?
| | Influenza, Human | 6 | 2018 | 88 | 0.580 |
Why?
| | Thrombosis | 1 | 2021 | 250 | 0.560 |
Why?
| | Anticoagulants | 1 | 2021 | 280 | 0.550 |
Why?
| | Dengue | 5 | 2016 | 7 | 0.510 |
Why?
| | RNA Processing, Post-Transcriptional | 3 | 2014 | 23 | 0.510 |
Why?
| | Female | 35 | 2025 | 28792 | 0.500 |
Why?
| | Child, Preschool | 22 | 2021 | 4164 | 0.490 |
Why?
| | Male | 34 | 2025 | 27444 | 0.490 |
Why?
| | Adult | 23 | 2025 | 14541 | 0.470 |
Why?
| | Epidemics | 4 | 2022 | 27 | 0.460 |
Why?
| | GATA1 Transcription Factor | 2 | 2017 | 7 | 0.450 |
Why?
| | Child | 29 | 2025 | 7384 | 0.440 |
Why?
| | Oncogene Proteins, Fusion | 4 | 2024 | 62 | 0.440 |
Why?
| | RNA, Ribosomal | 1 | 2014 | 16 | 0.430 |
Why?
| | RNA Precursors | 1 | 2014 | 9 | 0.420 |
Why?
| | Intensive Care Units | 4 | 2025 | 243 | 0.420 |
Why?
| | Codon, Initiator | 1 | 2014 | 8 | 0.420 |
Why?
| | Infant | 17 | 2021 | 3808 | 0.410 |
Why?
| | Malaria, Falciparum | 3 | 2020 | 24 | 0.410 |
Why?
| | Meningitis, Cryptococcal | 2 | 2010 | 10 | 0.410 |
Why?
| | Point Mutation | 1 | 2014 | 67 | 0.410 |
Why?
| | Enteral Nutrition | 2 | 2025 | 157 | 0.390 |
Why?
| | Aged | 13 | 2025 | 10430 | 0.390 |
Why?
| | Vaccination | 6 | 2024 | 310 | 0.380 |
Why?
| | Breast Neoplasms | 1 | 2021 | 1223 | 0.370 |
Why?
| | Middle Aged | 15 | 2025 | 13422 | 0.370 |
Why?
| | Science | 3 | 2021 | 22 | 0.360 |
Why?
| | Prognosis | 6 | 2024 | 2118 | 0.350 |
Why?
| | Cryptococcus neoformans | 2 | 2010 | 26 | 0.340 |
Why?
| | Artemisinins | 3 | 2020 | 10 | 0.330 |
Why?
| | Amplified Fragment Length Polymorphism Analysis | 1 | 2010 | 3 | 0.330 |
Why?
| | Mycological Typing Techniques | 1 | 2010 | 3 | 0.330 |
Why?
| | DNA, Fungal | 1 | 2010 | 41 | 0.320 |
Why?
| | Antimalarials | 3 | 2020 | 34 | 0.320 |
Why?
| | Disease Outbreaks | 5 | 2022 | 120 | 0.320 |
Why?
| | Gene Deletion | 1 | 2011 | 279 | 0.320 |
Why?
| | Drug Resistance, Multiple, Bacterial | 3 | 2025 | 56 | 0.310 |
Why?
| | Evolution, Molecular | 3 | 2021 | 97 | 0.310 |
Why?
| | Antibodies, Viral | 5 | 2021 | 109 | 0.310 |
Why?
| | Adolescent | 18 | 2025 | 6912 | 0.310 |
Why?
| | Typhoid Fever | 3 | 2015 | 4 | 0.300 |
Why?
| | Viruses | 3 | 2015 | 24 | 0.290 |
Why?
| | Malaria | 2 | 2020 | 37 | 0.290 |
Why?
| | Insulin, Isophane | 2 | 2025 | 3 | 0.290 |
Why?
| | Viral Vaccines | 2 | 2020 | 16 | 0.280 |
Why?
| | Hyperglycemia | 2 | 2025 | 90 | 0.270 |
Why?
| | Influenza A Virus, H5N1 Subtype | 4 | 2016 | 8 | 0.270 |
Why?
| | Dengue Vaccines | 2 | 2018 | 2 | 0.260 |
Why?
| | Young Adult | 14 | 2025 | 4514 | 0.260 |
Why?
| | Hand, Foot and Mouth Disease | 2 | 2018 | 2 | 0.260 |
Why?
| | Retrospective Studies | 7 | 2025 | 6821 | 0.260 |
Why?
| | Mycobacterium tuberculosis | 3 | 2018 | 250 | 0.260 |
Why?
| | Enterovirus | 2 | 2018 | 8 | 0.260 |
Why?
| | Polymorphism, Single Nucleotide | 5 | 2018 | 505 | 0.260 |
Why?
| | DNA Methylation | 6 | 2023 | 592 | 0.250 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 177 | 0.250 |
Why?
| | Information Dissemination | 2 | 2020 | 85 | 0.250 |
Why?
| | Coronavirus Infections | 2 | 2020 | 188 | 0.250 |
Why?
| | Dengue Virus | 2 | 2018 | 13 | 0.250 |
Why?
| | Prospective Studies | 6 | 2024 | 2412 | 0.240 |
Why?
| | Hypoglycemic Agents | 2 | 2025 | 227 | 0.240 |
Why?
| | Respiratory Syncytial Virus Infections | 2 | 2016 | 37 | 0.230 |
Why?
| | Communicable Diseases, Emerging | 2 | 2015 | 13 | 0.230 |
Why?
| | Incidence | 4 | 2025 | 1085 | 0.230 |
Why?
| | Exocrine Pancreatic Insufficiency | 1 | 2025 | 4 | 0.230 |
Why?
| | Viral Load | 3 | 2021 | 83 | 0.230 |
Why?
| | Lipomatosis | 1 | 2025 | 6 | 0.230 |
Why?
| | Bone Marrow Diseases | 1 | 2025 | 11 | 0.220 |
Why?
| | Kidney Function Tests | 1 | 2025 | 55 | 0.220 |
Why?
| | Blood Glucose | 2 | 2025 | 491 | 0.220 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2011 | 412 | 0.220 |
Why?
| | Enterovirus Infections | 2 | 2015 | 7 | 0.220 |
Why?
| | Swine Diseases | 2 | 2015 | 7 | 0.220 |
Why?
| | Creatinine | 1 | 2025 | 158 | 0.220 |
Why?
| | Respiratory Tract Infections | 2 | 2016 | 82 | 0.210 |
Why?
| | Nutritional Support | 1 | 2024 | 31 | 0.210 |
Why?
| | Lymphoma | 1 | 2025 | 71 | 0.210 |
Why?
| | Central Nervous System Infections | 2 | 2014 | 7 | 0.210 |
Why?
| | Hemophilia A | 1 | 2024 | 27 | 0.200 |
Why?
| | Adaptive Immunity | 2 | 2021 | 32 | 0.200 |
Why?
| | Drug Incompatibility | 1 | 2023 | 2 | 0.200 |
Why?
| | Genotype | 6 | 2018 | 563 | 0.200 |
Why?
| | Hemorrhage | 2 | 2024 | 226 | 0.200 |
Why?
| | Neuromuscular Blockade | 1 | 2023 | 14 | 0.190 |
Why?
| | Gene Rearrangement | 1 | 2024 | 76 | 0.190 |
Why?
| | Cell Cycle Proteins | 2 | 2021 | 170 | 0.190 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2024 | 333 | 0.190 |
Why?
| | Salmonella typhi | 2 | 2015 | 4 | 0.190 |
Why?
| | Osteosarcoma | 1 | 2023 | 44 | 0.190 |
Why?
| | Consensus | 1 | 2024 | 206 | 0.190 |
Why?
| | Tandem Mass Spectrometry | 1 | 2024 | 255 | 0.190 |
Why?
| | Tuberculosis, Pulmonary | 2 | 2018 | 106 | 0.190 |
Why?
| | World Health Organization | 4 | 2018 | 59 | 0.190 |
Why?
| | Infection Control | 2 | 2019 | 45 | 0.190 |
Why?
| | Genetic Variation | 5 | 2015 | 223 | 0.180 |
Why?
| | Tuberculosis, Meningeal | 2 | 2016 | 4 | 0.180 |
Why?
| | Chromosome Aberrations | 3 | 2017 | 297 | 0.180 |
Why?
| | Azacitidine | 2 | 2023 | 39 | 0.180 |
Why?
| | Leukemia, Myelomonocytic, Juvenile | 1 | 2022 | 15 | 0.180 |
Why?
| | Serum Albumin | 1 | 2022 | 56 | 0.180 |
Why?
| | Recurrence | 3 | 2022 | 694 | 0.170 |
Why?
| | Vaccines, Attenuated | 2 | 2018 | 11 | 0.170 |
Why?
| | Renal Replacement Therapy | 1 | 2022 | 51 | 0.170 |
Why?
| | Age Factors | 3 | 2021 | 1136 | 0.170 |
Why?
| | Risk Factors | 5 | 2025 | 4018 | 0.170 |
Why?
| | Bone Neoplasms | 1 | 2023 | 188 | 0.170 |
Why?
| | Biotechnology | 1 | 2021 | 15 | 0.170 |
Why?
| | Drug Dosage Calculations | 1 | 2021 | 11 | 0.170 |
Why?
| | Myelitis | 1 | 2021 | 1 | 0.170 |
Why?
| | Enterovirus D, Human | 1 | 2021 | 1 | 0.170 |
Why?
| | Central Nervous System Viral Diseases | 1 | 2021 | 2 | 0.170 |
Why?
| | Neoplasms, Second Primary | 1 | 2022 | 75 | 0.170 |
Why?
| | Plasmodium falciparum | 2 | 2020 | 26 | 0.170 |
Why?
| | Narration | 1 | 2021 | 28 | 0.170 |
Why?
| | Co-Repressor Proteins | 1 | 2021 | 17 | 0.170 |
Why?
| | Diabetes Mellitus | 1 | 2024 | 321 | 0.160 |
Why?
| | Erythrocyte Transfusion | 1 | 2021 | 53 | 0.160 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2021 | 36 | 0.160 |
Why?
| | Gene Regulatory Networks | 1 | 2021 | 112 | 0.160 |
Why?
| | Neuromuscular Diseases | 1 | 2021 | 31 | 0.160 |
Why?
| | Injury Severity Score | 1 | 2021 | 166 | 0.160 |
Why?
| | B-Lymphocytes | 1 | 2021 | 178 | 0.160 |
Why?
| | Kidney | 1 | 2025 | 717 | 0.160 |
Why?
| | Leadership | 1 | 2021 | 106 | 0.160 |
Why?
| | Zoonoses | 2 | 2021 | 11 | 0.160 |
Why?
| | Leucine | 1 | 2020 | 114 | 0.150 |
Why?
| | Chromatin | 1 | 2021 | 145 | 0.150 |
Why?
| | International Cooperation | 2 | 2017 | 52 | 0.150 |
Why?
| | Bacteremia | 1 | 2020 | 87 | 0.150 |
Why?
| | Blood Transfusion | 1 | 2020 | 127 | 0.150 |
Why?
| | Molecular Sequence Data | 5 | 2015 | 759 | 0.150 |
Why?
| | MicroRNAs | 2 | 2021 | 397 | 0.150 |
Why?
| | Respiratory Syncytial Virus, Human | 2 | 2016 | 14 | 0.150 |
Why?
| | Hemorrhagic Fever, Ebola | 2 | 2015 | 7 | 0.140 |
Why?
| | Ribosomes | 2 | 2009 | 33 | 0.140 |
Why?
| | Orthomyxoviridae | 1 | 2018 | 3 | 0.140 |
Why?
| | Sex Factors | 1 | 2021 | 747 | 0.140 |
Why?
| | Mosquito Control | 1 | 2018 | 4 | 0.140 |
Why?
| | Plasmodium | 1 | 2018 | 5 | 0.140 |
Why?
| | Immunization, Secondary | 1 | 2018 | 25 | 0.140 |
Why?
| | Base Sequence | 5 | 2014 | 620 | 0.140 |
Why?
| | DNA-Binding Proteins | 1 | 2021 | 423 | 0.140 |
Why?
| | Research Report | 1 | 2018 | 19 | 0.140 |
Why?
| | Genome, Viral | 2 | 2015 | 78 | 0.140 |
Why?
| | Influenza in Birds | 2 | 2016 | 5 | 0.140 |
Why?
| | Isoniazid | 1 | 2018 | 28 | 0.140 |
Why?
| | Animals | 14 | 2023 | 13528 | 0.140 |
Why?
| | Tuberculosis, Multidrug-Resistant | 1 | 2018 | 30 | 0.130 |
Why?
| | Treatment Outcome | 4 | 2023 | 5597 | 0.130 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2021 | 1367 | 0.130 |
Why?
| | Antitubercular Agents | 1 | 2018 | 89 | 0.130 |
Why?
| | Influenza A virus | 1 | 2017 | 16 | 0.130 |
Why?
| | Induction Chemotherapy | 1 | 2017 | 65 | 0.130 |
Why?
| | Tuberculosis | 1 | 2018 | 133 | 0.130 |
Why?
| | Parasitemia | 1 | 2017 | 6 | 0.130 |
Why?
| | Malaria, Cerebral | 1 | 2017 | 1 | 0.130 |
Why?
| | Glucosephosphate Dehydrogenase Deficiency | 1 | 2017 | 4 | 0.130 |
Why?
| | Endemic Diseases | 1 | 2017 | 26 | 0.130 |
Why?
| | Ribosome Subunits, Large, Eukaryotic | 2 | 2014 | 2 | 0.130 |
Why?
| | Agammaglobulinemia | 1 | 1996 | 9 | 0.130 |
Why?
| | X Chromosome | 1 | 1996 | 13 | 0.130 |
Why?
| | Protozoan Proteins | 1 | 2017 | 33 | 0.120 |
Why?
| | Genome, Human | 2 | 2021 | 121 | 0.120 |
Why?
| | Infant, Newborn | 4 | 2023 | 2913 | 0.120 |
Why?
| | Public Health Practice | 1 | 2017 | 42 | 0.120 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2016 | 8 | 0.120 |
Why?
| | Benzoxazines | 1 | 2016 | 18 | 0.120 |
Why?
| | Phenotype | 3 | 2021 | 803 | 0.120 |
Why?
| | Receptors, Colony-Stimulating Factor | 1 | 2016 | 1 | 0.120 |
Why?
| | Disease Susceptibility | 3 | 2021 | 96 | 0.120 |
Why?
| | Cell Proliferation | 4 | 2021 | 1031 | 0.120 |
Why?
| | CCAAT-Enhancer-Binding Proteins | 1 | 2016 | 14 | 0.120 |
Why?
| | Anemia | 1 | 2017 | 76 | 0.120 |
Why?
| | Enterovirus A, Human | 1 | 2016 | 1 | 0.120 |
Why?
| | HIV Infections | 2 | 2010 | 402 | 0.120 |
Why?
| | Neutropenia | 1 | 1996 | 113 | 0.120 |
Why?
| | Kobuvirus | 1 | 2015 | 2 | 0.120 |
Why?
| | Immunologic Factors | 2 | 2013 | 117 | 0.120 |
Why?
| | Ebola Vaccines | 1 | 2015 | 1 | 0.120 |
Why?
| | Models, Theoretical | 3 | 2021 | 180 | 0.120 |
Why?
| | Case-Control Studies | 4 | 2017 | 1212 | 0.120 |
Why?
| | Public-Private Sector Partnerships | 1 | 2015 | 8 | 0.120 |
Why?
| | Editorial Policies | 1 | 2015 | 14 | 0.120 |
Why?
| | Animals, Wild | 1 | 2015 | 10 | 0.120 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 579 | 0.110 |
Why?
| | Picornaviridae Infections | 1 | 2015 | 22 | 0.110 |
Why?
| | DNA Copy Number Variations | 1 | 2016 | 117 | 0.110 |
Why?
| | Hepatitis E | 1 | 2015 | 6 | 0.110 |
Why?
| | Earthquakes | 1 | 2015 | 5 | 0.110 |
Why?
| | Emergencies | 1 | 2015 | 78 | 0.110 |
Why?
| | Biomedical Technology | 1 | 2015 | 10 | 0.110 |
Why?
| | Azithromycin | 1 | 2015 | 25 | 0.110 |
Why?
| | DNA, Bacterial | 2 | 2018 | 167 | 0.110 |
Why?
| | Epidemiological Monitoring | 3 | 2021 | 15 | 0.110 |
Why?
| | Salmonella enterica | 1 | 2015 | 18 | 0.110 |
Why?
| | Research Support as Topic | 1 | 2015 | 44 | 0.110 |
Why?
| | Periodicals as Topic | 1 | 2015 | 63 | 0.110 |
Why?
| | Feces | 1 | 2015 | 160 | 0.110 |
Why?
| | Health Care Costs | 1 | 2016 | 178 | 0.110 |
Why?
| | Viral Envelope Proteins | 1 | 2014 | 31 | 0.110 |
Why?
| | Encephalitis, Viral | 2 | 2013 | 7 | 0.110 |
Why?
| | Registries | 1 | 2018 | 652 | 0.110 |
Why?
| | Ribosome Subunits, Small, Eukaryotic | 1 | 2014 | 2 | 0.110 |
Why?
| | Transcription Factors | 3 | 2024 | 571 | 0.110 |
Why?
| | K562 Cells | 1 | 2014 | 42 | 0.110 |
Why?
| | Virus Diseases | 1 | 2015 | 47 | 0.100 |
Why?
| | Health Policy | 1 | 2015 | 165 | 0.100 |
Why?
| | Chromosome Mapping | 3 | 2011 | 145 | 0.100 |
Why?
| | Antibodies, Neutralizing | 1 | 2014 | 78 | 0.100 |
Why?
| | Circoviridae | 1 | 2014 | 1 | 0.100 |
Why?
| | Circoviridae Infections | 1 | 2014 | 1 | 0.100 |
Why?
| | Tertiary Care Centers | 1 | 2014 | 86 | 0.100 |
Why?
| | Leukemia, Myeloid | 1 | 2014 | 40 | 0.100 |
Why?
| | Health Services Needs and Demand | 1 | 2015 | 163 | 0.100 |
Why?
| | Enteroviruses, Porcine | 1 | 2013 | 1 | 0.100 |
Why?
| | Molecular Epidemiology | 2 | 2010 | 38 | 0.100 |
Why?
| | Severity of Illness Index | 4 | 2024 | 1049 | 0.100 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2015 | 83 | 0.100 |
Why?
| | Anemia, Macrocytic | 1 | 2013 | 1 | 0.100 |
Why?
| | Prednisolone | 1 | 2013 | 56 | 0.100 |
Why?
| | Cluster Analysis | 2 | 2010 | 238 | 0.100 |
Why?
| | Cytogenetic Analysis | 1 | 2013 | 79 | 0.100 |
Why?
| | Cohort Studies | 3 | 2018 | 1557 | 0.100 |
Why?
| | Recombination, Genetic | 1 | 2013 | 95 | 0.100 |
Why?
| | China | 3 | 2020 | 135 | 0.090 |
Why?
| | Models, Biological | 2 | 2021 | 737 | 0.090 |
Why?
| | Phylogeny | 4 | 2015 | 231 | 0.090 |
Why?
| | RNA, Messenger | 4 | 2021 | 1133 | 0.090 |
Why?
| | Genomics | 1 | 2014 | 271 | 0.090 |
Why?
| | Advisory Committees | 2 | 2015 | 75 | 0.090 |
Why?
| | Nervous System Diseases | 1 | 2013 | 93 | 0.090 |
Why?
| | Heart Defects, Congenital | 1 | 2018 | 625 | 0.090 |
Why?
| | Amino Acid Sequence | 2 | 2015 | 563 | 0.090 |
Why?
| | Chromosome Deletion | 2 | 2013 | 138 | 0.090 |
Why?
| | Haploinsufficiency | 1 | 2011 | 15 | 0.090 |
Why?
| | Mosaicism | 1 | 2011 | 17 | 0.090 |
Why?
| | Genotyping Techniques | 1 | 2011 | 19 | 0.090 |
Why?
| | Blotting, Northern | 1 | 2011 | 106 | 0.090 |
Why?
| | Immune Evasion | 2 | 2021 | 15 | 0.090 |
Why?
| | Prevalence | 4 | 2018 | 1034 | 0.090 |
Why?
| | RNA, Small Interfering | 2 | 2008 | 214 | 0.080 |
Why?
| | Neoplastic Stem Cells | 2 | 2022 | 90 | 0.080 |
Why?
| | Pilot Projects | 2 | 2025 | 727 | 0.080 |
Why?
| | Genome-Wide Association Study | 1 | 2011 | 184 | 0.080 |
Why?
| | Cell Line | 2 | 2014 | 1016 | 0.080 |
Why?
| | Viremia | 1 | 2010 | 23 | 0.080 |
Why?
| | Bacterial Typing Techniques | 1 | 2010 | 37 | 0.080 |
Why?
| | Daunorubicin | 2 | 2022 | 15 | 0.080 |
Why?
| | WT1 Proteins | 1 | 2009 | 4 | 0.080 |
Why?
| | Cytarabine | 2 | 2022 | 44 | 0.080 |
Why?
| | Viral Nonstructural Proteins | 1 | 2010 | 60 | 0.080 |
Why?
| | Outpatients | 2 | 2024 | 131 | 0.080 |
Why?
| | Enterobacteriaceae | 1 | 2009 | 9 | 0.080 |
Why?
| | Enterobacteriaceae Infections | 1 | 2009 | 18 | 0.070 |
Why?
| | Plasmids | 1 | 2009 | 165 | 0.070 |
Why?
| | Quinolones | 1 | 2009 | 52 | 0.070 |
Why?
| | Semliki forest virus | 1 | 2008 | 1 | 0.070 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2008 | 18 | 0.070 |
Why?
| | Seasons | 2 | 2020 | 92 | 0.070 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 2009 | 131 | 0.070 |
Why?
| | DNA, Viral | 3 | 2015 | 136 | 0.070 |
Why?
| | Pedigree | 1 | 2008 | 128 | 0.070 |
Why?
| | Seroepidemiologic Studies | 2 | 2018 | 43 | 0.070 |
Why?
| | Pandemics | 2 | 2024 | 595 | 0.070 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2007 | 15 | 0.070 |
Why?
| | Wilms Tumor | 1 | 2007 | 18 | 0.070 |
Why?
| | Genes, Tumor Suppressor | 1 | 2007 | 73 | 0.060 |
Why?
| | Neuraminidase | 1 | 2007 | 4 | 0.060 |
Why?
| | Oseltamivir | 1 | 2007 | 5 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 2 | 2007 | 533 | 0.060 |
Why?
| | Receptors, Interleukin-1 | 1 | 2006 | 18 | 0.060 |
Why?
| | DNA Helicases | 1 | 2008 | 148 | 0.060 |
Why?
| | Toll-Like Receptors | 1 | 2006 | 25 | 0.060 |
Why?
| | Mice | 4 | 2023 | 5982 | 0.060 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2007 | 140 | 0.060 |
Why?
| | Cell Differentiation | 2 | 2021 | 681 | 0.060 |
Why?
| | Alleles | 2 | 2017 | 277 | 0.060 |
Why?
| | Quinolines | 2 | 2017 | 44 | 0.060 |
Why?
| | Treatment Failure | 2 | 2018 | 119 | 0.060 |
Why?
| | Kidney Neoplasms | 1 | 2007 | 181 | 0.060 |
Why?
| | Antiviral Agents | 1 | 2007 | 179 | 0.060 |
Why?
| | DNA | 1 | 2008 | 535 | 0.050 |
Why?
| | Tacrolimus | 1 | 2005 | 61 | 0.050 |
Why?
| | Graft vs Host Disease | 1 | 2005 | 93 | 0.050 |
Why?
| | Hypoglycemia | 1 | 2025 | 62 | 0.050 |
Why?
| | Glomerular Filtration Rate | 1 | 2025 | 128 | 0.050 |
Why?
| | Sus scrofa | 2 | 2015 | 38 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2020 | 2318 | 0.050 |
Why?
| | Drug Administration Schedule | 1 | 2025 | 370 | 0.050 |
Why?
| | Autoimmune Diseases | 1 | 2005 | 90 | 0.050 |
Why?
| | Transcriptome | 2 | 2017 | 368 | 0.050 |
Why?
| | Nucleosome Assembly Protein 1 | 1 | 2024 | 1 | 0.050 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2024 | 19 | 0.050 |
Why?
| | Factor VIII | 1 | 2024 | 24 | 0.050 |
Why?
| | Mass Screening | 2 | 2018 | 362 | 0.050 |
Why?
| | Practice Guidelines as Topic | 1 | 2007 | 502 | 0.050 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2024 | 14 | 0.050 |
Why?
| | Proto-Oncogenes | 1 | 2024 | 27 | 0.050 |
Why?
| | DEAD-box RNA Helicases | 1 | 2024 | 34 | 0.050 |
Why?
| | Haplotypes | 2 | 2017 | 96 | 0.050 |
Why?
| | Sequence Analysis, DNA | 2 | 2015 | 216 | 0.050 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2015 | 181 | 0.050 |
Why?
| | Retinoblastoma-Binding Protein 2 | 1 | 2023 | 6 | 0.050 |
Why?
| | Nuclear Pore Complex Proteins | 1 | 2023 | 10 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2024 | 33 | 0.050 |
Why?
| | Uncertainty | 1 | 2023 | 46 | 0.050 |
Why?
| | Trauma Centers | 1 | 2025 | 210 | 0.050 |
Why?
| | Viral Proteins | 2 | 2015 | 164 | 0.050 |
Why?
| | Autoantibodies | 1 | 2024 | 120 | 0.050 |
Why?
| | Swine | 2 | 2015 | 440 | 0.050 |
Why?
| | Nepal | 2 | 2015 | 12 | 0.050 |
Why?
| | Time Factors | 2 | 2020 | 2992 | 0.050 |
Why?
| | CpG Islands | 1 | 2023 | 114 | 0.050 |
Why?
| | Apoptosis | 1 | 2008 | 1139 | 0.050 |
Why?
| | Ambulatory Care | 1 | 2024 | 239 | 0.050 |
Why?
| | Pharmaceutical Preparations | 1 | 2023 | 74 | 0.050 |
Why?
| | Disease Management | 1 | 2024 | 187 | 0.050 |
Why?
| | Computational Biology | 1 | 2024 | 209 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2025 | 933 | 0.050 |
Why?
| | Point-of-Care Systems | 2 | 2015 | 68 | 0.050 |
Why?
| | Poultry | 2 | 2016 | 25 | 0.040 |
Why?
| | Insulin | 1 | 2024 | 493 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-cbl | 1 | 2022 | 3 | 0.040 |
Why?
| | Core Binding Factor beta Subunit | 1 | 2021 | 4 | 0.040 |
Why?
| | Myosin Heavy Chains | 1 | 2021 | 26 | 0.040 |
Why?
| | Strategic Stockpile | 1 | 2021 | 1 | 0.040 |
Why?
| | Emigration and Immigration | 1 | 2021 | 18 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 2 | 2015 | 276 | 0.040 |
Why?
| | Laboratories | 1 | 2021 | 21 | 0.040 |
Why?
| | RNA | 1 | 2022 | 173 | 0.040 |
Why?
| | Risk Assessment | 2 | 2017 | 1368 | 0.040 |
Why?
| | Spatio-Temporal Analysis | 1 | 2021 | 11 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2021 | 1517 | 0.040 |
Why?
| | Immunization Schedule | 1 | 2021 | 11 | 0.040 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2021 | 32 | 0.040 |
Why?
| | Selection, Genetic | 1 | 2021 | 27 | 0.040 |
Why?
| | Chronic Disease | 1 | 2023 | 581 | 0.040 |
Why?
| | Africa | 1 | 2020 | 13 | 0.040 |
Why?
| | Acetylation | 1 | 2021 | 97 | 0.040 |
Why?
| | Enhancer Elements, Genetic | 1 | 2021 | 60 | 0.040 |
Why?
| | Antibody-Dependent Enhancement | 1 | 2020 | 2 | 0.040 |
Why?
| | Biological Evolution | 1 | 2021 | 55 | 0.040 |
Why?
| | RNA-Binding Proteins | 1 | 2021 | 133 | 0.040 |
Why?
| | Trans-Activators | 1 | 2021 | 139 | 0.040 |
Why?
| | Cross Reactions | 1 | 2020 | 42 | 0.040 |
Why?
| | Genetic Association Studies | 1 | 2021 | 124 | 0.040 |
Why?
| | Communicable Disease Control | 1 | 2020 | 37 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 235 | 0.040 |
Why?
| | Adaptation, Physiological | 1 | 2021 | 109 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2021 | 310 | 0.040 |
Why?
| | Survival Rate | 2 | 2015 | 949 | 0.040 |
Why?
| | Truth Disclosure | 1 | 2020 | 15 | 0.040 |
Why?
| | Up-Regulation | 1 | 2021 | 456 | 0.040 |
Why?
| | Receptors, GABA-A | 1 | 2019 | 10 | 0.040 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2021 | 187 | 0.040 |
Why?
| | Epidemiologic Methods | 1 | 2019 | 47 | 0.040 |
Why?
| | Forecasting | 1 | 2020 | 152 | 0.040 |
Why?
| | History, 19th Century | 1 | 2019 | 21 | 0.040 |
Why?
| | Drug Resistance, Microbial | 1 | 2019 | 44 | 0.040 |
Why?
| | Immunity, Innate | 1 | 2020 | 112 | 0.040 |
Why?
| | History, 21st Century | 1 | 2019 | 60 | 0.040 |
Why?
| | History, 20th Century | 1 | 2019 | 97 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2023 | 1470 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2024 | 820 | 0.040 |
Why?
| | Protein Binding | 1 | 2021 | 670 | 0.040 |
Why?
| | Hematopoietic Stem Cells | 1 | 2021 | 189 | 0.040 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2024 | 610 | 0.040 |
Why?
| | Histones | 1 | 2021 | 318 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2020 | 412 | 0.040 |
Why?
| | Interprofessional Relations | 1 | 2020 | 95 | 0.040 |
Why?
| | Tropical Climate | 1 | 2018 | 12 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 640 | 0.040 |
Why?
| | Japan | 1 | 2018 | 42 | 0.040 |
Why?
| | Antigens, Viral | 1 | 2018 | 44 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2020 | 320 | 0.030 |
Why?
| | Case Management | 1 | 2018 | 43 | 0.030 |
Why?
| | Sputum | 1 | 2018 | 65 | 0.030 |
Why?
| | Rifampin | 1 | 2018 | 57 | 0.030 |
Why?
| | Etoposide | 1 | 2017 | 71 | 0.030 |
Why?
| | United States | 2 | 2021 | 5413 | 0.030 |
Why?
| | Public Health Surveillance | 1 | 2017 | 18 | 0.030 |
Why?
| | Computer Simulation | 1 | 2018 | 290 | 0.030 |
Why?
| | Urban Population | 1 | 2018 | 162 | 0.030 |
Why?
| | Erythroid Cells | 1 | 2017 | 5 | 0.030 |
Why?
| | Genes, Dominant | 1 | 2017 | 22 | 0.030 |
Why?
| | Erythropoiesis | 1 | 2017 | 18 | 0.030 |
Why?
| | Genes, X-Linked | 1 | 2017 | 7 | 0.030 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 2017 | 5 | 0.030 |
Why?
| | Erythrocytes | 1 | 2017 | 70 | 0.030 |
Why?
| | Health Personnel | 1 | 2020 | 259 | 0.030 |
Why?
| | Gene Frequency | 1 | 2017 | 97 | 0.030 |
Why?
| | Drug Combinations | 1 | 2017 | 138 | 0.030 |
Why?
| | Bacterial Proteins | 2 | 2010 | 349 | 0.030 |
Why?
| | Models, Genetic | 1 | 2017 | 169 | 0.030 |
Why?
| | Alkynes | 1 | 2016 | 6 | 0.030 |
Why?
| | Cyclopropanes | 1 | 2016 | 27 | 0.030 |
Why?
| | Protein-Tyrosine Kinases | 1 | 1996 | 87 | 0.030 |
Why?
| | Blood-Brain Barrier | 1 | 2016 | 51 | 0.030 |
Why?
| | Efficiency | 1 | 2016 | 33 | 0.030 |
Why?
| | Africa, Western | 1 | 2015 | 5 | 0.030 |
Why?
| | Quality-Adjusted Life Years | 1 | 2016 | 67 | 0.030 |
Why?
| | Disease Reservoirs | 1 | 2015 | 4 | 0.030 |
Why?
| | Access to Information | 1 | 2015 | 21 | 0.030 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2015 | 49 | 0.030 |
Why?
| | Immunization Programs | 1 | 2015 | 21 | 0.030 |
Why?
| | Viral Hepatitis Vaccines | 1 | 2015 | 5 | 0.030 |
Why?
| | Basic Reproduction Number | 1 | 2015 | 1 | 0.030 |
Why?
| | Phylogeography | 1 | 2015 | 6 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2017 | 465 | 0.030 |
Why?
| | Health Priorities | 1 | 2015 | 19 | 0.030 |
Why?
| | Meteorological Concepts | 1 | 2015 | 2 | 0.030 |
Why?
| | Protein Conformation | 1 | 2015 | 174 | 0.030 |
Why?
| | Diarrhea | 1 | 2015 | 96 | 0.030 |
Why?
| | Pharynx | 1 | 2015 | 31 | 0.030 |
Why?
| | Family Health | 1 | 2015 | 78 | 0.030 |
Why?
| | Genome, Bacterial | 1 | 2015 | 60 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 274 | 0.030 |
Why?
| | Biological Assay | 1 | 2014 | 46 | 0.030 |
Why?
| | Immunoblotting | 1 | 2014 | 118 | 0.030 |
Why?
| | Gene Expression | 1 | 2017 | 618 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2017 | 466 | 0.030 |
Why?
| | Models, Molecular | 1 | 2015 | 352 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 233 | 0.030 |
Why?
| | Child Health Services | 1 | 2015 | 79 | 0.030 |
Why?
| | Malawi | 1 | 2014 | 15 | 0.030 |
Why?
| | Methylation | 1 | 2014 | 127 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2017 | 412 | 0.030 |
Why?
| | Placebos | 1 | 2013 | 80 | 0.030 |
Why?
| | Geography | 1 | 2014 | 65 | 0.030 |
Why?
| | Sequence Alignment | 1 | 2014 | 119 | 0.030 |
Why?
| | Immunomodulation | 1 | 2013 | 36 | 0.020 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2013 | 17 | 0.020 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2013 | 67 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2017 | 1569 | 0.020 |
Why?
| | Killer Cells, Natural | 1 | 2013 | 113 | 0.020 |
Why?
| | Models, Statistical | 1 | 2014 | 229 | 0.020 |
Why?
| | Parents | 1 | 2016 | 341 | 0.020 |
Why?
| | Thalidomide | 1 | 2013 | 378 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2014 | 477 | 0.020 |
Why?
| | Virology | 1 | 2010 | 5 | 0.020 |
Why?
| | Coma | 1 | 2010 | 17 | 0.020 |
Why?
| | Cytokines | 1 | 2013 | 627 | 0.020 |
Why?
| | Cryptococcus gattii | 1 | 2010 | 1 | 0.020 |
Why?
| | Flucytosine | 1 | 2010 | 13 | 0.020 |
Why?
| | DNA Gyrase | 1 | 2010 | 2 | 0.020 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2010 | 16 | 0.020 |
Why?
| | Algorithms | 1 | 2014 | 668 | 0.020 |
Why?
| | Immunoassay | 1 | 2010 | 23 | 0.020 |
Why?
| | High-Throughput Screening Assays | 1 | 2010 | 39 | 0.020 |
Why?
| | Amphotericin B | 1 | 2010 | 105 | 0.020 |
Why?
| | Drug Resistance, Bacterial | 1 | 2010 | 80 | 0.020 |
Why?
| | RNA, Viral | 1 | 2010 | 123 | 0.020 |
Why?
| | Carrier State | 1 | 2009 | 10 | 0.020 |
Why?
| | Alphavirus | 1 | 2008 | 1 | 0.020 |
Why?
| | Retroviridae | 1 | 2008 | 5 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2009 | 466 | 0.020 |
Why?
| | Culex | 1 | 2008 | 5 | 0.020 |
Why?
| | Anaerobiosis | 1 | 2008 | 21 | 0.020 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2008 | 46 | 0.020 |
Why?
| | Transduction, Genetic | 1 | 2008 | 44 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2008 | 109 | 0.020 |
Why?
| | Species Specificity | 1 | 2008 | 191 | 0.020 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2009 | 177 | 0.020 |
Why?
| | Pregnancy | 1 | 2015 | 2610 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2010 | 869 | 0.020 |
Why?
| | Antifungal Agents | 1 | 2010 | 350 | 0.020 |
Why?
| | Ankyrin Repeat | 1 | 2007 | 4 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2007 | 69 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2015 | 3495 | 0.020 |
Why?
| | Signal Transduction | 1 | 2014 | 1748 | 0.020 |
Why?
| | Birds | 1 | 2007 | 14 | 0.020 |
Why?
| | Fibroblasts | 1 | 2008 | 363 | 0.020 |
Why?
| | Program Development | 1 | 2007 | 165 | 0.010 |
Why?
| | Absorption | 1 | 2005 | 21 | 0.010 |
Why?
| | Polymorphism, Genetic | 1 | 2006 | 181 | 0.010 |
Why?
| | Oxygen | 1 | 2008 | 338 | 0.010 |
Why?
| | Administration, Topical | 1 | 2005 | 62 | 0.010 |
Why?
| | Bone Marrow Transplantation | 1 | 2005 | 110 | 0.010 |
Why?
| | Skin Diseases | 1 | 2005 | 117 | 0.010 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2007 | 868 | 0.010 |
Why?
|
|
Farrar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|